Latent Labs — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Latent Labs is a well-funded, private AI-native biotechnology company pioneering the application of frontier generative models to molecular design. Founded by alumni of DeepMind's AlphaFold project, the company has developed a suite of AI platforms, including Latent-Y, Latent-X, and Latent-X2, focused on de novo protein and drug design. Backed by top-tier venture capital and angel investors from leading AI organizations, Latent Labs operates as a platform technology company, partnering with other entities to advance programs while building its internal capabilities in both AI and wet-lab validation.

AI / Machine Learning

Technology Platform

Suite of frontier generative AI models for molecular design, including Latent-Y (autonomous AI agent for drug design), Latent-X2 (for antibody design), and Latent-X (for de novo protein binder design). Combines AI/ML with experimental validation platforms.

Opportunities

The company is positioned at the convergence of two explosive fields: generative AI and biotechnology.

Its general-purpose models for molecular design can address vast markets in therapeutic antibody discovery, enzyme optimization for sustainable manufacturing, and novel therapeutic modality creation.

Successful validation could make it a foundational platform partner for the entire biopharma industry.

Risk Factors

Key risks include the high technical uncertainty of generating clinically viable molecules with AI, intense competition from other well-funded AI biotechs and internal pharma efforts, and the unproven scalability of the platform partnership business model in biotech.

Demonstrating consistent real-world utility beyond benchmarks is critical.

Competitive Landscape

Latent Labs operates in the highly competitive AI-driven drug discovery space, competing with pure-play AI biotechs (e.g., Recursion, Exscientia, Genesis), tech giant spin-offs (e.g., Isomorphic Labs from Alphabet), and a growing number of startups. Its key differentiators are its deep AlphaFold heritage, focus on frontier generative models (vs. more narrow AI), and its development of an autonomous AI agent (Latent-Y) for end-to-end design.

More companies in Synthetic Biology →More companies in United Kingdom →